CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleMarket cap is $244.62M, lower than 95% of all stocks globally
- PositionPrice-to-book is 0.66×, lower than 95% of its Biotechnology peers (median 2.86×)
- Interpretations3 currently firing — 3
Sign in to view price data.
Sign inWhat the company actually pays, and whether its own cash supports it.
Dividends view
Yield
1.21%
Annual Rate
HKD 0.07Paid annual
Payout Ratio
10.0%Sustainable
Last Ex-Dividend
Jun 17, 2026
The reported statements, read against the company's own industry.
Financials view
Market Capitalization
1.92BHKD244.62M · vs all stocks (USD)
Trailing P/E
8.08xvs Biotechnology peers
Revenue (TTM)
1.52BCNY193.83M · vs all stocks (USD)
Profit Margin
10.74%vs Biotechnology peers
52-Week Change
-54.69%vs all stocks
Market Capitalization
1.92BHKD244.62M · vs all stocks (USD)
Enterprise Value
973.15MHKD124.05M · vs all stocks (USD)
Trailing P/E
8.08xvs Biotechnology peers
Price to Sales (TTM)
1.00xvs Biotechnology peers
Price to Book (MRQ)
0.6603xvs Biotechnology peers
Enterprise to Revenue
0.6400xvs Biotechnology peers
Enterprise to EBITDA
4.48xvs Biotechnology peers
Profit Margin
10.74%vs Biotechnology peers
Operating Margin
16.09%vs Biotechnology peers
Return on Assets (TTM)
4.52%vs Biotechnology peers
Return on Equity (TTM)
8.49%vs Biotechnology peers
Revenue (TTM)
1.52BCNY193.83M · vs all stocks (USD)
Revenue per Share (TTM)
5.33CNYUpdated Sep 20, 2026Quarterly Revenue Growth
-1.20%vs Biotechnology peers
Gross Profit (TTM)
1.22BCNY155.36M · vs all stocks (USD)
EBITDA (TTM)
211.76MCNY26.99M · vs all stocks (USD)
Net Income (TTM)
163.36MCNY20.82M · vs all stocks (USD)
Quarterly Earnings Growth (YoY)
1.20%vs Biotechnology peers
Operating Cash Flow (TTM)
254.84MCNY32.48M · vs all stocks (USD)
Levered Free Cash Flow (TTM)
138.41MCNY17.64M · vs all stocks (USD)
Trailing Annual Dividend Rate
0.0655HKDUpdated Sep 20, 2026Trailing Annual Dividend Yield
1.21%vs all stocks
Payout Ratio
9.96%vs Biotechnology peers
Revenue
1.31BCNYFY2025 · Dec 31, 2025Cost of Goods Sold
252.24MCNYFY2025 · Dec 31, 2025Gross Profit
1.05BCNYFY2025 · Dec 31, 2025Operating Income
159.53MCNY23.81M · vs all stocks (USD)
Pre-tax Income
161.52MCNYFY2025 · Dec 31, 2025Income Tax Expense
23.12MCNYFY2025 · Dec 31, 2025Net Income
138.41MCNYFY2025 · Dec 31, 2025EBIT
167.19MCNYFY2025 · Dec 31, 2025EBITDA (Income Statement)
211.76MCNYFY2025 · Dec 31, 2025Research & Development
123.66MCNYFY2025 · Dec 31, 2025Selling, General & Administrative
547.89MCNYFY2025 · Dec 31, 2025Non-operating Interest Income
10.52MCNYFY2025 · Dec 31, 2025Non-operating Interest Expense
5.66MCNYFY2025 · Dec 31, 2025Preferred Stock Dividends
0.00CNYFY2025 · Dec 31, 2025Operating Cash Flow
195.59MCNYFY2025 · Dec 31, 2025Free Cash Flow
146.08MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
348.67MCNYFY2025 · Dec 31, 2025Starting Profit (CF Statement)
161.52MCNYFY2025 · Dec 31, 2025Stock-based Compensation
5.55MCNYFY2025 · Dec 31, 2025Other Non-cash Items
-4.86MCNYFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
41.35MCNYFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-7.98MCNYFY2025 · Dec 31, 2025Capital Expenditures
-49.51MCNYFY2025 · Dec 31, 2025Net Intangibles (CF)
-55.06MCNYFY2025 · Dec 31, 2025Purchase of Investments
-300.00MCNYFY2025 · Dec 31, 2025Net Investing Cash Flow
-349.51MCNYFY2025 · Dec 31, 2025Long-term Debt Issuance
114.90MCNYFY2025 · Dec 31, 2025Long-term Debt Payments
-132.10MCNYFY2025 · Dec 31, 2025Common Dividends Paid
-13.73MCNYFY2025 · Dec 31, 2025Net Financing Cash Flow
-30.93MCNYFY2025 · Dec 31, 2025Shares Outstanding
245.40MSharesUpdated Sep 20, 2026Float Shares
64.30MSharesUpdated Sep 20, 2026% Held by Insiders
84.97%vs all stocks
% Held by Institutions
0.03%vs all stocks
Total Cash (MRQ)
774.90MCNY98.78M · vs all stocks (USD)
Total Cash per Share (MRQ)
2.75CNYUpdated Sep 20, 2026Total Debt (MRQ)
222.12MCNY28.31M · vs all stocks (USD)
Total Debt to Equity (MRQ)
0.1124xvs Biotechnology peers
Current Ratio (MRQ)
4.29xvs Biotechnology peers
Book Value per Share (MRQ)
8.20CNYUpdated Sep 20, 2026Total Assets
2.12BCNY316.04M · vs all stocks (USD)
Total Current Assets
1.48BCNYFY2025 · Dec 31, 2025Total Liabilities
469.74MCNYFY2025 · Dec 31, 2025Total Non-current Assets
634.81MCNYFY2025 · Dec 31, 2025Total Non-current Liabilities
137.35MCNYFY2025 · Dec 31, 2025Total Current Liabilities
332.39MCNYFY2025 · Dec 31, 2025Cash
348.67MCNYFY2025 · Dec 31, 2025Cash & Cash Equivalents
348.67MCNYFY2025 · Dec 31, 2025Other Short-term Investments
365.79MCNYFY2025 · Dec 31, 2025Accounts Receivable
571.06MCNYFY2025 · Dec 31, 2025Inventory
149.75MCNYFY2025 · Dec 31, 2025Accounts Payable
48.38MCNYFY2025 · Dec 31, 2025Short-term Debt
48.94MCNYFY2025 · Dec 31, 2025Long-term Debt
112.68MCNYFY2025 · Dec 31, 2025Common Stock (Book)
245.40MCNYFY2025 · Dec 31, 2025Retained Earnings
246.52MCNYFY2025 · Dec 31, 2025Total Shareholders' Equity
1.65BCNY245.95M · vs all stocks (USD)
52-Week Low
4.60HKDUpdated Sep 20, 202652-Week High
12.71HKDUpdated Sep 20, 202652-Week Change
-54.69%vs all stocks
50-Day MA
5.41HKDUpdated Sep 20, 2026200-Day MA
7.06HKDUpdated Sep 20, 2026Avg 10-Day Volume
53.48KSharesUpdated Sep 20, 2026Avg 30-Day Volume
34.67KSharesUpdated Sep 20, 2026Diluted EPS (TTM)
0.6700CNYUpdated Sep 20, 20263 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
MRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Cash covers most of its debt, with earnings high against its liabilities.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
Industry-Benchmarked Return on Capital Elevated
It earns more on its assets and its equity than its industry, and gets more sales from those assets.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Peer Positioning
Price-to-book is 0.66×, lower than 95% of its Biotechnology peers (median 2.86×)Notable
Price-to-book: 0.66Industry median: 2.86Industry P5: 0.98Peers compared: 260
Financial Health
Altman Z-Score 3.79: safe zoneNotable
Altman Z-Score: 3.79
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Market cap is $244.62M, lower than 95% of all stocks globallySignificant
Market cap (USD): 244,617,302.982Global P5: 275,556,405.438
Companies that share the same coordination system — how they create, deliver, or capture value.
Sisram Medical Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Seikagaku Corporation
Tier 1ProductionApproval-Gated PipelineRule
Siga Technologies Inc.
Tier 1ProductionApproval-Gated PipelineRule
Lyell Immunopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Niagen Bioscience Inc.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Heartseed Inc.
Tier 1ProductionApproval-Gated PipelineRule
Akebia Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Entrada Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
Terrascend Corp.
Tier 1ProductionApproval-Gated PipelineRuleFlow
United Orthopedic Corporation
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Yamaichi Electronics Co., Ltd.
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Friedrich Vorwerk Group SE
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities
Filtronic Plc
3 interpretationsIndustry-Benchmarked ROA and Margin ElevatedIndustry-Benchmarked Return on Capital ElevatedMRQ Cash Elevated Relative To Total Debt With EBITDA And FCF Elevated Relative To Total Liabilities